Under the EU Biocidal Products Regulation (EC) No. 528/2012, applicants for product authorisation have a duty to provide a qualitative and quantitative assessment of Disinfectant-By-Products (DBP) formation from the use of their products and if necessary, perform a risk assessment to identify conditions for safe use.
Over 120 members comprising halogenated active substance manufacturers, formulators and distributors have joined the DBP Consortium.
The Consortium covers all Product Types (PT) but the main focus of work are the major PT where halogenated chemistry is predominantly applied; PT 1- 5, 11 and 12. There are also many members supporting in-situ generated active substances, particularly active chlorine generation.
The benefit of joining the Consortium is that it provides a sharing of costs and knowledge in this complex field.
By having a joint industry approach the consortium is working to:
- reduce the cost burden on applicants for compliance with this mandatory data requirement,
- prevent the need for repeat testing on marker DBP substances if needed for risk assessment purposes
- ensure that all halogenated products are evaluated in accordance with the same DBP data set.
The aim is to generate, through risk assessment, a harmonised standard for both chlorinated and brominated biocidal products, i.e. a worst case DBP profile for each disinfectant/preservative use will be identified and assessed for safety. This should generate a list of label claims (dosing regime and application conditions) that lead to a safe use, in respect to DBP generation, that applicants can reference for their own authorisations.
If you wish to request membership, please contact Mrs Elicia Hodgson from Arrow Regulatory (email@example.com).